Published Case Report Demonstrates the Clinical Utility of Biocept’s CTC Platform in the Management of Patients with Metastatic Breast Cancer

Published Case Report Demonstrates the Clinical Utility of Biocept’s CTC Platform in the Management of Patients with Metastatic Breast Cancer

June 18, 2018 Peer-reviewed article in journal Clinics in Oncology highlights ability of Biocept’s Target Selector™ to detect a key biomarker to qualify breast cancer patients for targeted therapy when tissue biopsy is inconclusive SAN DIEGO, June 18, 2018 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC),